Swiss Life Sciences Stock News

Earnings trigger puts Berner Kantonalbank in focus Berner Kantonalbank (SWX:BEKN) has drawn investor attention after publishing its full year 2025 results, which show lower net interest income and net income and indicate slightly weaker profitability compared with the previous year. See our latest analysis for Berner Kantonalbank. The earnings release comes after a strong rebound in the share price, with a 10.78% 1 month share price return and 29.04% 3 month share price return, contributing...

UBS Group (SWX:UBSG) has secured final approval for a US national banking licence, a regulatory step that allows the Swiss group to add everyday banking products alongside its existing US wealth management offerings. See our latest analysis for UBS Group. Despite the new US banking licence and a proposed cancellation of 63,776,550 repurchased shares, momentum has cooled, with a 30 day share price return of 10.34% decline and a year to date share price return of 22.95% decline, even as the 5...

Cosmo Pharmaceuticals at NVIDIA GTC: Why This AI Conference Matters for Investors Cosmo Pharmaceuticals (SWX:COPN) is set to present at the NVIDIA GTC AI Conference on March 19 in San Jose, putting its MedTech AI capabilities and GI Genius platform in front of a focused AI audience. See our latest analysis for Cosmo Pharmaceuticals. Cosmo’s share price has had a weak short term run, with a 30 day share price return of 33.31% decline and a year to date decline of 24.57%. However, the 1 year...

Earnings event puts INFICON’s 2025 profitability in focus INFICON Holding (SWX:IFCN) has released full year 2025 results, reporting sales of US$673.72 million compared with US$670.95 million a year earlier. Net income was US$85.82 million, down from US$112.75 million. This shift has put profit trends under closer scrutiny for shareholders. See our latest analysis for INFICON Holding. The earnings release, which showed relatively steady sales but a lower net income, comes as INFICON’s 1 year...

Earnings event puts Medartis Holding (SWX:MED) in focus Medartis Holding (SWX:MED) is back on investors’ radar after reporting full year 2025 results, with higher sales, net income and earnings per share, followed by a special call on the same day. See our latest analysis for Medartis Holding. At a share price of CHF83.0, the stock has a 1 day share price return of 4.93% but a 30 day share price return that reflects a 12.17% decline. The 1 year total shareholder return of 9.35% suggests...

Metall Zug FY 2025 earnings snapshot Metall Zug (SWX:METN) has kicked off FY 2025 with first half revenue of CHF 94.2 million and a net income loss of CHF 9.8 million, setting a cautious tone around profitability. Over the recent reporting periods, revenue has shifted from CHF 181.2 million in the first half of 2024 to CHF 102.2 million in the second half and then CHF 94.2 million in the first half of 2025. Net results moved from a profit of CHF 55.6 million to a loss of CHF 3.0 million and...

Compagnie Financière Tradition (SWX:CFT) drew fresh attention after reporting full year 2025 results, with consolidated revenue up 11.4%, EBITDA up 24.6%, net income at CHF 134.2 million, and a proposed 11.1% dividend increase. See our latest analysis for Compagnie Financière Tradition. At a share price of CHF262.0, the stock has a 1-day share price return of 2.34%, set against a weaker 90-day share price return of an 8.39% decline. The 1-year total shareholder return of 33.52% and 5-year...

In recent weeks, SaltX Technology announced a Joint Development Agreement with Holcim to co-develop and pilot a fully electrified, fossil-free clinker production process in Europe, targeting the world’s first fully electric cement plant by 2028 and advancing electrified calcination and sintering technologies that can be retrofitted or built into new facilities. By pairing this deep-process electrification push with Holcim’s broader moves in low‑carbon manufacturing and equipment procurement,...

Galderma Group stock: recent performance snapshot Galderma Group (SWX:GALD) has drawn fresh attention after a period of mixed share performance, including a 0.3% move over the past day and a negative return over the past month and past 3 months. See our latest analysis for Galderma Group. That recent 7 day and 90 day share price weakness, with a 7 day share price return of a 1.93% decline and a 90 day share price return of a 13.16% decline from CHF142.5, contrasts with a 1 year total...

Emmi dropped from FTSE All-World Index puts index-tracking flows in focus Emmi (SWX:EMMN) has been removed from the FTSE All-World Index (USD), an index change that can influence trading activity for funds tracking the benchmark and draw attention to the company’s CHF 4.36b market value. See our latest analysis for Emmi. Emmi’s latest index exit comes after a 90 day share price return of 11.8% and a year to date share price return of 14.0%, while the 1 year total shareholder return of 3.4%...

Index removal puts Adecco in focus for income minded investors Adecco Group (SWX:ADEN) has been removed from the FTSE All-World Index (USD), a shift that can prompt portfolio adjustments by index trackers, while its confirmed CHF 1.00 per share annual dividend keeps income considerations in view. See our latest analysis for Adecco Group. At a share price of CHF18.21, Adecco’s 30 day share price return of 15.46% and year to date share price return of 22.38%, alongside a 1 year total...

DKSH Holding (SWX:DKSH) has been removed from the FTSE All-World Index (USD), an index change that can influence trading flows as index-tracking investors and funds rebalance their portfolios. See our latest analysis for DKSH Holding. At a share price of CHF57.4, DKSH Holding has seen a 9.32% 1 month share price decline and a 19.05% 1 year total shareholder return decline, suggesting momentum has been fading even before the index removal headline. If this kind of index reshuffle has you...

Idorsia (SWX:IDIA) is back in focus after announcing that CEO Dr. Srishti Gupta will step down and also leave the Board of Directors. Chairman Jean Paul Clozel will take over as interim CEO. See our latest analysis for Idorsia. The leadership change comes after a mixed period for investors, with the latest CHF3.15 share price sitting against a 1 day share price return of 2.27%, a 30 day share price return of a 14.75% decline, and a very large 1 year total shareholder return of about 3x...

Compagnie Financière Tradition (SWX:CFT) has reported FY 2025 results with first half revenue of CHF 575.4 million and basic EPS of CHF 9.14, while trailing twelve month revenue came in at about CHF 1.1 billion with EPS of CHF 16.25 and earnings growth of 21.7% over the past year. Over recent periods the company has seen revenue move from CHF 533.4 million and EPS of CHF 7.98 in 1H 2024 to CHF 510.5 million and EPS of CHF 7.13 in 2H 2024, before reaching the latest 1H 2025 levels. This sets...

Liechtensteinische Landesbank (SWX:LLBN) has drawn investor attention after issuing a CHF 200 million senior preferred bond, a ten year fixed rate instrument that met strong demand and references the bank’s solid capital position. See our latest analysis for Liechtensteinische Landesbank. The bond issue comes as the share price trades at CHF98.8, with a 1-day share price return of 1.96% and a 90-day share price return of 18.61%. The 1-year total shareholder return of 28.92% and 5-year total...

Novartis (SWX:NOVN) agreed to acquire a selective breast cancer therapy targeting PI3Kα mutations from Synnovation Therapeutics for up to US$3b. The oral therapy is aimed at HR+/HER2- breast cancer with PI3Kα mutations, addressing a major unmet treatment need. The deal is intended to strengthen Novartis's targeted oncology portfolio in a competitive cancer drug market. For investors watching big pharma, this move puts a fresh spotlight on Novartis's focus on targeted cancer medicines...

Assessing Alcon after recent share price pressure Alcon (SWX:ALC) has come under pressure recently, with the share price showing negative returns over the past month and past 3 months. This puts the focus on what current fundamentals might imply for investors. See our latest analysis for Alcon. Beyond the recent pullback, Alcon’s share price return has been weak over the year, and the 1 year total shareholder return of a 26.9% decline underlines that pressure has been sustained rather than a...

Galderma Group (SWX:GALD) has scheduled a virtual Annual General Meeting that will focus on corporate governance changes. The AGM agenda includes new board nominations linked to major shareholder L’Oréal and a proposed dividend. Management plans to discuss L’Oréal’s influence as an investor following a period of record company performance. Galderma Group operates in the dermatology and skincare segment, an area that continues to attract consumer interest as spending on skin health and...

Roche Holding (SWX:ROG) has drawn investor attention after recent price moves, with the share price around CHF 322.30 and mixed short term returns contrasting with stronger multi year total return figures. See our latest analysis for Roche Holding. Recent trading has been choppy, with a 1 month share price return showing a decline of 10.47% and a year to date share price return showing a decline of 0.98%, contrasting with a 1 year total shareholder return of 10.30%. This suggests that recent...

If you are wondering whether UBS Group's current share price offers value or just noise, the recent performance gives you plenty to think about. The stock trades at CHF 29.08, with a 0.7% decline over the last week, a 12.9% decline over the last month, a 23.8% decline year to date, a 4.2% gain over 1 year, 83.3% over 3 years and 120.0% over 5 years. These moves sit against a backdrop of ongoing integration work following the Credit Suisse acquisition and continuing market attention on UBS...

Swiss Re (SWX:SREN) has attracted fresh attention after striking a US$2b longevity reinsurance deal with Athene, its first covering US retirees and a step that broadens its role in global pension risk transfer. See our latest analysis for Swiss Re. The longevity deal and recent leadership change in the Asia Pacific life and health unit come as Swiss Re’s share price sits at CHF128.0, with a small year to date share price decline and a much stronger multi year total shareholder return profile...

Recent share performance and business overview SMG Swiss Marketplace Group Holding (SWX:SMG) has drawn interest after a period of weaker share performance, with the stock closing at CHF 26.35 and showing negative returns over the past week, month and past 3 months. The company runs online marketplaces across real estate, automotive and general classifieds in Switzerland. It earned CHF 358.843m in revenue and CHF 67.694m in net income, supported by reported annual revenue and net income growth...

Nestlé Holdings has completed a major cash tender offer for its outstanding notes, purchasing all securities that were validly tendered. The transaction used available liquidity and may have involved intra group distributions from Nestlé, affecting how debt is positioned within the group. This liability management move changes the mix of outstanding debt and could affect interest costs and balance sheet flexibility over time. For readers tracking SWX:NESN, this development comes with the...

Partners Group Holding (SWX:PGHN) is back in the spotlight after a Bank of America note highlighted its exposure to potential private credit shocks, just as the chair mentioned a possible doubling of default rates. See our latest analysis for Partners Group Holding. The recent Bank of America note appears to have reinforced concerns around private credit risk. This lines up with Partners Group Holding's 1 month share price return of 14.86% decline and year to date share price return of 22.02%...